The Impact of Immune Checkpoint Inhibitors-Induced Skin Toxicity on Patients’ Quality of Life and the Role of Dermatologic Intervention-Reference-Cited by-同舟云学术

The Impact of Immune Checkpoint Inhibitors-Induced Skin Toxicity on Patients’ Quality of Life and the Role of Dermatologic Intervention

Published:2024-07-31 Issue:3 Volume:14 Page:e2024118
ISSN:2160-9381
Container-title:Dermatology Practical & Conceptual
language:
Short-container-title:

Author:

Kemanetzi Christina¹,Lallas Konstantinos²,Lazaridou Elisavet¹,Papageorgiou Chrysoula¹,Lallas Aimilios³,Stratigos Alexandros⁴,Timotheadou Eleni²,Lazaridis George²,Dionysopoulos Dimitrios²,Kalaitzi Kalliopi⁵,Tsimpidakis Antonios⁴,Trakatelli Myrto¹,Patsatsi Aikaterini¹,Nikolaou Vasiliki⁴,Apalla Zoe¹

Affiliation:

1. Second Department of Dermatology, School of Health Sciences, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Greece

2. Oncology Department, School of Health Sciences, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Greece

3. First Department of Dermatology, School of Health Sciences, Aristotle University of Thessaloniki, Greece

4. First Department of Dermatology-Venereology, National and Kapodistrian University of Athens, School of Medicine, Andreas Sygros Hospital, Athens, Greece

5. Attikon Hospital, Athens Medical School, Athens, Greece

Abstract

Introduction: Data regarding quality of life (QoL) of oncologic patients experiencing dermatologic immune-related adverse events (dirAEs)and their course after dermatologic intervention are scarce. Objectives To assess the impact of dirAEs on patients' QoL and to investigate the correlation between dermatologic and oncologic indexes used for estimating QoL. Methods We enrolled oncologic patients with dirAEs managed in two supportive oncodermatology outpatient clinics in Greece. Patient-reported outcomes included DLQI, EORTC-QLQ-C30 and Numerical Rating Scale for pruritus (pNRS). Results Overall, 110 patients were enrolled in the study. Mean(SD) DLQI and pNRS scores were 15.54 (5.44) and7.25 (2.95), correspondingly, while functional, symptom and summary scores of EORTC-C30 were 79.17 (2.11), 17.66 (3.60) and 80.67 (3.08), respectively. After therapeutic interventions, there was a statistically significant decrease in DLQI scores after1st intervention compared to baseline, and 2nd intervention compared to 1st [mean (SD) decrease 4.38 (2.91), p<0.001 and 5.16 (3.99), p<0.001, respectively]. DLQI showed no correlation with global health status/QoLs (rho 0.01, p=0.90) of EORTC-C30. Conclusions dirAEs negatively affect QoL. Dermatologic intervention improves patients’ QoL, facilitating an unimpaired oncologic treatment. Poor correlation between DLQI and EORTC-QLQ-30 highlights the need for adapted QoL measurement tools in the context of ICIs treatment.

Publisher

Mattioli1885

Reference30 articles.

1. Weber JS, Hodi FS, Wolchok JD et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 2017; 35: 785-792.

2. Haanen J, Carbonnel F, Robert C et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28: 119–42.

3. Belum VR, Benhuri B, Postow MA et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 2016; 60: 12–25.

4. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521–32.

5. Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol 2016; 28: 254–63.